28 november 2019 07:19:24

SUZHOU, China, Nov. 27, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (`Innovent`) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today jointly announced with Eli Lilly and Company (`Lilly`) that the innovative PD-1 inhibitor TyvytŪ (sintilimab injection), co-developed by both companies, is the only PD-1 inhibitor that has been included in the new Catalogue of National Reimbursement Drug List (`NRDL`) according to the latest announcement from the National Healthcare Security Administration (`NHSA`). (Details of medical insurance reimbursement and...